LumiraDx (LumiraDx) Debt-to-Asset : 1.18 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Debt-to-Asset?

LumiraDx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $310.29 Mil. LumiraDx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $92.47 Mil. LumiraDx's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $341.61 Mil. LumiraDx's debt to asset for the quarter that ended in Jun. 2023 was 1.18.

LumiraDx Debt-to-Asset Historical Data

The historical data trend for LumiraDx's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Debt-to-Asset Chart

LumiraDx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

0.58

0.52

0.90

LumiraDx Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Asset	Get a 7-Day Free Trial								0.68	0.68	0.90	1.02	1.18

Competitive Comparison of LumiraDx's Debt-to-Asset

For the Diagnostics & Research subindustry, LumiraDx's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LumiraDx's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, LumiraDx's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where LumiraDx's Debt-to-Asset falls into.

LumiraDx Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

LumiraDx's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(9.225	+	388.782)	/	441.013
	=	0.90

LumiraDx's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(310.291	+	92.466)	/	341.607
	=	1.18

LumiraDx (OTCPK:LMDWF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

LumiraDx Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of LumiraDx's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

LumiraDx (LumiraDx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

LMDXF:USA

Address

C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108

Website

https://www.lumiradx.com

LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.